An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)

What is the purpose of this trial?

This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, randomised Phase 1b study in patients with muscle invasive bladder cancer (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetics and anti-tumour activity of multiple agents as monotherapy and as combinations of different novel anti-cancer agents in patients with muscle invasive bladder cancer.

The study will consist of a number of study modules (substudies), each evaluating the safety and tolerability of a specific agent or combination.

Participation Guidelines

Ages: 18 - 130 years

Gender: Both

Astra Zeneca, L.P.

Start Date: 05/18/2017

End Date: 02/16/2018

Last Updated: 02/22/2018

Study HIC#: 1601017024

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email or call 1-877-978-8348.

Trial Image